[ Home ] [ Controlled Substances ] [ Stimulants ]
NEA
|
Etilamfetamine (Apetinil) is a stimulant drug of amphetamine chemical class. It is an N-substituted amphetamine with an ethyl group on the amphetamine backbone. It was used as an anorectic or appetite suppressant. Etilamfetamine is a psychoactive drug, which can be used as a recreational drug. Etilamfetamine has been abused as a "designer drug" alternative to amphetamine and possibly methamphetamine. It is a dopamine releasing agent.
Etilamfetamine (Apetinil):
https://drugs.ncats.io/drug/022YON1XMX
https://www.caymanchem.com/msdss/11557m.pdf
It was invented in the early 20th century and was subsequently used as an anorectic or appetite suppressant in the 1950s, but was not as commonly used as other amphetamines. was largely discontinued once newer drugs such as phenmetrazine were introduced. It most likely acts primarily as a dopamine releasing agent. Its activity as a norepinephrine or serotonin releasing agent is not known. Ethylamphetamine can be used as a recreational drug and, while its prevalence is less than amphetamine's, it is still encountered as a substance taken for recreational purposes. Ethylamphetamine produces effects similar to amphetamine and methamphetamine, though its potency is less. At equipotent dosage, ethylamphetamine is subjectively less euphorigenic.
NEA puts more money behind novel Parkinson's pill - Brenig Therapeutics, a neurology-focused drug development company using an AI-based discovery platform, has closed a $65 million series A financing. Tuesday July 23, 2024 - thepharmaletter.com Cardurion Builds Cardiovascular Pipeline with $260M Series B Financing - Cardurion Pharmaceuticals has completed a $260 million Series B financing, with proceeds intended to advance its pipeline of cardiovascular drugs, as well as acquire additional therapeutic assets ... Brenig Therapeutics Announces $65 Million Series A Financing to Advance Leading Pre-Clinical Parkinson's Disease Pipeline - Brenig Therapeutics Inc. (Brenig), a pioneering neurology-focused drug development company utilizing an AI/ML-based discovery platform, today announced the closing of a $65 million Series A financing. Union With Labor Dispute of Its Own Threatened To Cut Off Workers’ Health Benefits - The National Education Association, the nation’s largest union, told striking workers that their health coverage would be cut off Aug. 1 absent a deal on a new contract. Tensions have mounted after ... Vanessa Chettle talks about battling drug addiction, relationships and being dumped by friends - Vanessa Chettle was among the socialites who ruled the showbiz industry back then. But eight years down the line, Vanessa has sunk into oblivion. NEA: Income Boosts Keep Boosting The Market Price - The purpose of this article is to evaluate the Nuveen AMT-Free Quality Municipal Income Fund (NYSE:NEA) as an investment option at its current market price. This is a multi-state, closed-end fund ... AI-powered drug development, VW teams up with Rivian and DEI is ‘bad’ - First up, we’ve got Formation Bio, an AI-focused drug development startup that just raised a whopping $372 million in Series D funding, led by Andreessen Horowitz. This brings their total ... Nuveen AMT-Free Quality Muni Inc NEA - We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ... Cardurion raises another $260M to fuel heart drug pipeline - The financing, which ranks as one of the year’s larger private rounds, will help the startup advance a pair of drugs and potentially acquire other medicines. Cardurion Raises $260M Series B Financing - Proceeds will be used to support later-stage clinical trials with the company’s two lead drug candidates. Nuveen AMT-Free Quality Municipal Income Fund Common Shares of Beneficial Interest Par Value $.01 (NEA) Dividend History - The Dividend History page provides a single page to review all of the aggregated Dividend payment information. Visit our Dividend Calendar: Please note that the dividend history for Nasdaq stocks ... Magenta Medical raises $105M for world’s smallest heart pump - Magenta Medical announced today that it closed a $105 million financing round to support Elevate, its miniature heart pump technology.
| ||
| Stimulants | Link to this page |